Anthem Biosciences Limited files SEBI Takeover Regulations disclosure
Anthem Biosciences, a listed pharmaceutical company, has submitted a Regulation 31 disclosure to NSE under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Regulation 31(4) and 31(5) require disclosure by the acquirer within 2 working days of acquisition/crossing a slab of shares. The filing does not yet disclose the acquirer's identity, shareholding %, or offer price in the headline; these are detailed in the form DIS-4 appended to the NSE announcement.
Why it mattersFiling under Reg 31(4)–31(5) indicates acquisition of ≥5% stake (or crossing a slab threshold), obligating disclosure within 2 working days and potentially triggering open offer obligations if acquirer breaches 25% threshold; counsel must confirm whether acquirer is obliged to launch a mandatory offer.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Disclosure Filing (NSE Archives) · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026